Health inequity has been a longstanding global dilemma – one that I personally feel compelled to help address, especially in oncology. In fact, one of the reasons why I decided to join Takeda Oncology was the company’s commitment to improving health equity, not just for patients in the U.S. or Europe, but truly worldwide..

In recent years, we’ve seen remarkable progress in combatting devastating cancers, with the rise of immunotherapies across a breadth of therapeutic modalities, from antibody-based immunomodulators to cell-based therapies to other emerging technologies.

Over the past two decades, advancements in the industry have shifted how we diagnose, classify and ultimately treat certain cancers according to an individual’s molecular profile – a practice known as precision medicine. What does this transformative approach, and the diagnostics needed to achieve it, mean for the oncology industry, and most importantly, for patients with cancer? What gaps still remain, and how can stakeholders come together to address them?